Amiprofos methyl
Based on 1 Customer Validation
Amiprofos methyl (BAY-NTN 6867) is a phosphoric amide herbicide. Amiprofos methyl is a specific and potent antimicrotubule agent. Amiprofos methyl directly poisons microtubule dynamics in plant cells.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.37%
- No. CAS: 36001-88-4
- Fòrmula: C11H17N2O4PS
- Peso molecular:304.30
-
Almacenamiento:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Cytoskeleton Compound Library
HY-L060
-
Anti-Lung Cancer Compound Library
HY-L075
-
Protein-protein Interaction Inhibitor Library
HY-L109
-
Highly Selective Inhibitors Library
HY-L158
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Environmental Pollutant Compound Library
HY-L247
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Aging Compound Library
HY-L034
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HFF | IC50 |
1 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
1.5 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235V mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
10 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin F24H mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
19.1 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243S mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
2.1 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin V4L mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
28.5 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin L136F mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
28.5 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin T239I mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
3.3 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin S6I mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
3.9 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235L mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
5.1 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin H28Q mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
5.9 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin R243C mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
| HFF | IC50 |
7.1 μM
Compound: 1, APM
|
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay
Antimicrobial activity against Toxoplasma gondii RH containing alpha1-tubulin I235T mutation infected in HFF cells by plaque assay
|
[PMID: 20145086] |
Amiprofos methyl (APM) inhibits competitively the binding of [14C]oryzalin to tubulin with a Ki=5 μM. Amiprofos methyl concentrations inhibiting tobacco cell growth were within the threshold range of Amiprofos methyl concentrations that depolymerized cellular microtubules, indicating that growth inhibition is caused by microtubules depolymerization[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
No. CAS 36001-88-4
-
Appearance Solid
-
Peso molecular 304.30
-
Fòrmula C11H17N2O4PS
-
Color Off-white to light yellow
-
SMILES
S=P(OC)(NC(C)C)OC1=CC=C(C)C=C1[N+]([O-])=O
-
Synonyms
BAY-NTN 6867
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
DMSO : 100 mg/mL (328.62 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 2.5 mg/mL (8.22 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.22 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (274 KB)
-
SDS (392 KB)
- English - EN (392 KB)
- Français - FR (392 KB)
- Deutsch - DE (392 KB)
- Norwegian - NO (392 KB)
- Español - ES (392 KB)
- Swedish - SV (392 KB)
- Italian - IT (392 KB)
- Korean - KR (392 KB)
- Portuguese - PT (392 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Morejohn LC, et al. Inhibition of Plant Microtubule Polymerization in vitro by the Phosphoric Amide Herbicide Amiprophos-Methyl. Science. 1984;224(4651):874-876. [Content Brief]
[2]. Murthy JV, et al. Competitive Inhibition of High-Affinity Oryzalin Binding to Plant Tubulin by the Phosphoric Amide Herbicide Amiprophos-Methyl. Plant Physiol. 1994;105(1):309-320. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.2862 mL | 16.4312 mL | 32.8623 mL | 82.1558 mL |
| 5 mM | 0.6572 mL | 3.2862 mL | 6.5725 mL | 16.4312 mL | |
| 10 mM | 0.3286 mL | 1.6431 mL | 3.2862 mL | 8.2156 mL | |
| 15 mM | 0.2191 mL | 1.0954 mL | 2.1908 mL | 5.4771 mL | |
| 20 mM | 0.1643 mL | 0.8216 mL | 1.6431 mL | 4.1078 mL | |
| 25 mM | 0.1314 mL | 0.6572 mL | 1.3145 mL | 3.2862 mL | |
| 30 mM | 0.1095 mL | 0.5477 mL | 1.0954 mL | 2.7385 mL | |
| 40 mM | 0.0822 mL | 0.4108 mL | 0.8216 mL | 2.0539 mL | |
| 50 mM | 0.0657 mL | 0.3286 mL | 0.6572 mL | 1.6431 mL | |
| 60 mM | 0.0548 mL | 0.2739 mL | 0.5477 mL | 1.3693 mL | |
| 80 mM | 0.0411 mL | 0.2054 mL | 0.4108 mL | 1.0269 mL | |
| 100 mM | 0.0329 mL | 0.1643 mL | 0.3286 mL | 0.8216 mL |
Amiprofos methyl Related Classifications
HY-111939 Related Classifications
Powered by Bioz